During the past decade, Ohio GI and Liver Institute conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ohio GI and Liver Institute" #1 sponsor was "Pfizer" with 2 trials, followed by "Celgene" with 1 trials sponsored, "Cristcot LLC" with 1 trials sponsored, "Dartmouth-Hitchcock Medical Center" with 1 trials sponsored and "Genfit" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ohio GI and Liver Institute" #1 collaborator was "Agency for Healthcare Research and Quality (AHRQ)" with 1 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Atlanta Gastroenterology Associates" with 1 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator and "Cedars-Sinai Medical Center" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Ohio GI and Liver Institute" are "Crohn's Disease" (2 trials), "Crohn Disease" (1 trials), "Eosinophilic Esophagitis" (1 trials), "Nonalcoholic Steatohepatitis (NASH) With Fibrosis" (1 trials) and "Osteoarthritis" (1 trials). Many other conditions were trialed in "Ohio GI and Liver Institute" in a lesser frequency.

Most popular intervention types in "Ohio GI and Liver Institute" are "Drug" (4 trials), "Behavioral" (1 trials), "Biological" (1 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Elafibranor" (1 trials), "Etrasimod" (1 trials), "Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator" (1 trials) and "Ozanimod" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ohio GI and Liver Institute" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Ohio GI and Liver Institute". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Ohio GI and Liver Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Ohio GI and Liver Institute, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".